Oxford BioMedica shares fall 15% in one day

▤ Summary

Oxford BioMedica shares fell 15% in one day even after the company reported a positive half-year trading update. The company said first-half 2026 revenue grew 9% to about £80 million. It also rejected several takeover offers from EQT, though management appears open to a take-private deal from other private equity firms. Oxford BioMedica remains a London-listed cell and gene therapy developer that has also manufactured COVID vaccines for AstraZeneca and now focuses on autoimmune diseases and cancer therapies.

▦ Linked Companies